Which has better earnings & valuation, GLSI or GLAS?

Glass House Brands has higher revenue and earnings than Greenwich LifeSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A Glass House Brands $176.02M 4.38 N/A N/A N/A

Is GLSI or GLAS more profitable?

Glass House Brands' return on equity of 0.00% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -941.15% -368.53% Glass House Brands N/A N/A N/A

Does the media favor GLSI or GLAS?

In the previous week, Greenwich LifeSciences had 8 more articles in the media than Glass House Brands. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 1 mentions for Glass House Brands. Greenwich LifeSciences' average media sentiment score of 1.49 beat Glass House Brands' score of 0.00 indicating that Greenwich LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenwich LifeSciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glass House Brands 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, SLDB or GLSI?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.95 N/A Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A

Is SLDB or GLSI more profitable?

Solid Biosciences' return on equity of -73.42% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -73.42% -61.13% Greenwich LifeSciences N/A -941.15% -368.53%

Does the media favor SLDB or GLSI?

In the previous week, Greenwich LifeSciences had 6 more articles in the media than Solid Biosciences. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 3 mentions for Solid Biosciences. Greenwich LifeSciences' average media sentiment score of 1.49 beat Solid Biosciences' score of 1.28 indicating that Greenwich LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Greenwich LifeSciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CYRX or GLSI?

In the previous week, Greenwich LifeSciences had 5 more articles in the media than CryoPort. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 4 mentions for CryoPort. Greenwich LifeSciences' average media sentiment score of 1.49 beat CryoPort's score of 0.60 indicating that Greenwich LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Greenwich LifeSciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GLSI or ACRS?

In the previous week, Greenwich LifeSciences had 5 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 4 mentions for Aclaris Therapeutics. Greenwich LifeSciences' average media sentiment score of 1.49 beat Aclaris Therapeutics' score of 1.24 indicating that Greenwich LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenwich LifeSciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, DSGN or GLSI?

Design Therapeutics is trading at a lower price-to-earnings ratio than Greenwich LifeSciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Design Therapeutics N/A N/A -$69.79M -$1.20 N/A Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A

Is DSGN or GLSI more profitable?

Design Therapeutics' return on equity of -33.07% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% Greenwich LifeSciences N/A -941.15% -368.53%

Does the media favor DSGN or GLSI?

In the previous week, Greenwich LifeSciences had 6 more articles in the media than Design Therapeutics. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 3 mentions for Design Therapeutics. Greenwich LifeSciences' average media sentiment score of 1.49 beat Design Therapeutics' score of 0.39 indicating that Greenwich LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Greenwich LifeSciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Greenwich LifeSciences (GLSI) Competitors

$13.50 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$13.96 +0.47 (+3.44%)

As of 07/31/2026 07:34 PM Eastern

Compare

GLSI vs. GLAS, SLDB, CYRX, ACRS, and DSGN

Should you buy Greenwich LifeSciences stock or one of its competitors? MarketBeat compares Greenwich LifeSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Greenwich LifeSciences include Glass House Brands (GLAS), Solid Biosciences (SLDB), CryoPort (CYRX), Aclaris Therapeutics (ACRS), and Design Therapeutics (DSGN).

How does Greenwich LifeSciences compare to Glass House Brands?

Greenwich LifeSciences (NASDAQ:GLSI) and Glass House Brands (NYSE:GLAS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Glass House Brands has higher revenue and earnings than Greenwich LifeSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A
Glass House Brands	$176.02M	4.38	N/A	N/A	N/A

Greenwich LifeSciences currently has a consensus target price of $57.00, indicating a potential upside of 322.22%. Glass House Brands has a consensus target price of $17.00, indicating a potential upside of 76.81%. Given Greenwich LifeSciences' higher probable upside, research analysts plainly believe Greenwich LifeSciences is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Glass House Brands	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Glass House Brands' return on equity of 0.00% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-941.15%	-368.53%
Glass House Brands	N/A	N/A	N/A

In the previous week, Greenwich LifeSciences had 8 more articles in the media than Glass House Brands. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 1 mentions for Glass House Brands. Greenwich LifeSciences' average media sentiment score of 1.49 beat Glass House Brands' score of 0.00 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glass House Brands	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.2% of Greenwich LifeSciences shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Greenwich LifeSciences beats Glass House Brands on 6 of the 11 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Solid Biosciences' return on equity of -73.42% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Greenwich LifeSciences	N/A	-941.15%	-368.53%

Solid Biosciences has a beta of 2.41, meaning that its stock price is 141% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Solid Biosciences presently has a consensus price target of $17.11, suggesting a potential upside of 112.30%. Greenwich LifeSciences has a consensus price target of $57.00, suggesting a potential upside of 322.22%. Given Greenwich LifeSciences' higher probable upside, analysts plainly believe Greenwich LifeSciences is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

In the previous week, Greenwich LifeSciences had 6 more articles in the media than Solid Biosciences. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 3 mentions for Solid Biosciences. Greenwich LifeSciences' average media sentiment score of 1.49 beat Solid Biosciences' score of 1.28 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Greenwich LifeSciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Solid Biosciences beats Greenwich LifeSciences on 8 of the 14 factors compared between the two stocks.

How does Greenwich LifeSciences compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

CryoPort has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.32	$78.30M	$1.35	11.18
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

In the previous week, Greenwich LifeSciences had 5 more articles in the media than CryoPort. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 4 mentions for CryoPort. Greenwich LifeSciences' average media sentiment score of 1.49 beat CryoPort's score of 0.60 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Greenwich LifeSciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of CryoPort shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 9.5% of CryoPort shares are held by insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CryoPort has a net margin of 41.57% compared to Greenwich LifeSciences' net margin of 0.00%. CryoPort's return on equity of -7.92% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Greenwich LifeSciences	N/A	-941.15%	-368.53%

CryoPort presently has a consensus target price of $16.38, indicating a potential upside of 8.52%. Greenwich LifeSciences has a consensus target price of $57.00, indicating a potential upside of 322.22%. Given Greenwich LifeSciences' higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

CryoPort has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Summary

CryoPort beats Greenwich LifeSciences on 11 of the 15 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Aclaris Therapeutics?

Greenwich LifeSciences (NASDAQ:GLSI) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Greenwich LifeSciences had 5 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 4 mentions for Aclaris Therapeutics. Greenwich LifeSciences' average media sentiment score of 1.49 beat Aclaris Therapeutics' score of 1.24 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Greenwich LifeSciences has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Greenwich LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A
Aclaris Therapeutics	$7.83M	92.75	-$64.92M	-$0.56	N/A

Greenwich LifeSciences presently has a consensus price target of $57.00, indicating a potential upside of 322.22%. Aclaris Therapeutics has a consensus price target of $11.50, indicating a potential upside of 121.15%. Given Greenwich LifeSciences' higher possible upside, equities analysts clearly believe Greenwich LifeSciences is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Greenwich LifeSciences has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-941.15%	-368.53%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

Greenwich LifeSciences has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Summary

Greenwich LifeSciences and Aclaris Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Design Therapeutics' return on equity of -33.07% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Greenwich LifeSciences	N/A	-941.15%	-368.53%

Design Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 35.47%. Greenwich LifeSciences has a consensus target price of $57.00, indicating a potential upside of 322.22%. Given Greenwich LifeSciences' higher probable upside, analysts plainly believe Greenwich LifeSciences is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Greenwich LifeSciences had 6 more articles in the media than Design Therapeutics. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 3 mentions for Design Therapeutics. Greenwich LifeSciences' average media sentiment score of 1.49 beat Design Therapeutics' score of 0.39 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Greenwich LifeSciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Design Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Design Therapeutics is trading at a lower price-to-earnings ratio than Greenwich LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

Summary

Design Therapeutics beats Greenwich LifeSciences on 8 of the 14 factors compared between the two stocks.

Get Greenwich LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLSI vs. The Competition

Export

Metric	Greenwich LifeSciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$198.18M	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-8.60	7.38	282.27	24.66
Price / Sales	N/A	1,190.93	563.88	76.67
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	450.00	16.79	10.93	6.07
Net Income	-$19.36M	-$12.56M	$3.49B	$347.99M
7 Day Performance	0.45%	-1.79%	-0.61%	-0.42%
1 Month Performance	-38.64%	-8.42%	-3.75%	-4.80%
1 Year Performance	21.73%	48.61%	62.10%	18.61%

Greenwich LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLSI Greenwich LifeSciences	3.0302 of 5 stars	$13.50 flat	$57.00 +322.2%	+21.7%	$198.15M	N/A	N/A	3	Gap Down
GLAS Glass House Brands	N/A	$9.82 -2.9%	$17.00 +73.0%	N/A	$788.67M	$176.02M	N/A	N/A	Gap Up
SLDB Solid Biosciences	2.4775 of 5 stars	$7.88 -0.1%	$17.11 +117.2%	+18.0%	$771.85M	N/A	N/A	100	Positive News Gap Up
CYRX CryoPort	2.8386 of 5 stars	$15.29 +0.9%	$16.38 +7.1%	+107.6%	$770.67M	$176.18M	11.33	1,186	Upcoming Earnings
ACRS Aclaris Therapeutics	2.5909 of 5 stars	$5.27 -1.9%	$11.50 +118.4%	+239.9%	$734.05M	$7.83M	N/A	100	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLSI) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Greenwich LifeSciences (GLSI) Competitors

GLSI vs. GLAS, SLDB, CYRX, ACRS, and DSGN

How does Greenwich LifeSciences compare to Glass House Brands?

Summary

How does Greenwich LifeSciences compare to Solid Biosciences?

Summary

How does Greenwich LifeSciences compare to CryoPort?

Summary

How does Greenwich LifeSciences compare to Aclaris Therapeutics?

Summary

How does Greenwich LifeSciences compare to Design Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI vs. The Competition

Greenwich LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Greenwich LifeSciences (GLSI) Competitors

GLSI vs. GLAS, SLDB, CYRX, ACRS, and DSGN

How does Greenwich LifeSciences compare to Glass House Brands?

Which has better earnings & valuation, GLSI or GLAS?

Do analysts recommend GLSI or GLAS?

Is GLSI or GLAS more profitable?

Does the media favor GLSI or GLAS?

Do insiders and institutionals have more ownership in GLSI or GLAS?

Summary

How does Greenwich LifeSciences compare to Solid Biosciences?

Is SLDB or GLSI more profitable?

Which has more volatility & risk, SLDB or GLSI?

Do analysts recommend SLDB or GLSI?

Do institutionals and insiders hold more shares of SLDB or GLSI?

Which has preferable earnings & valuation, SLDB or GLSI?

Does the media favor SLDB or GLSI?

Summary

How does Greenwich LifeSciences compare to CryoPort?

Which has higher valuation & earnings, CYRX or GLSI?

Does the media refer more to CYRX or GLSI?

Do institutionals and insiders have more ownership in CYRX or GLSI?

Is CYRX or GLSI more profitable?

Do analysts prefer CYRX or GLSI?

Which has more volatility & risk, CYRX or GLSI?

Summary

How does Greenwich LifeSciences compare to Aclaris Therapeutics?

Do insiders and institutionals believe in GLSI or ACRS?

Does the media prefer GLSI or ACRS?

Which has better valuation & earnings, GLSI or ACRS?

Do analysts prefer GLSI or ACRS?

Is GLSI or ACRS more profitable?

Which has more volatility and risk, GLSI or ACRS?

Summary

How does Greenwich LifeSciences compare to Design Therapeutics?

Is DSGN or GLSI more profitable?

Do analysts recommend DSGN or GLSI?

Does the media favor DSGN or GLSI?

Which has more risk and volatility, DSGN or GLSI?

Do insiders & institutionals have more ownership in DSGN or GLSI?

Which has preferable valuation & earnings, DSGN or GLSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI vs. The Competition

Greenwich LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools